The stock plummeted approximately 22% to reach 46 cents per share. In light of these circumstances, Eight Capital analyst Ty Collin revised his price target for Canopy Growth, setting it at $0 instead of C$1.75 ($1.32) per share. Collin also reiterated a sell rating for the company, stating that it is no longer appropriate to consider Canopy Growth as a viable business.
As the movement for marijuana legalization gains momentum across the United States, a significant barrier…
Conventional treatments prescribed to treat autoimmune conditions are focused on taming inflammation; these usually include…
Discover deals like daily $10 eighths for the holiday weekend and beyond at Giving Tree…
Verilife Non-Medical Cannabis is now available in Ohio. Open to customers 21+ with a valid…
At Verilife, there's always a stocked selection of top products & new favorites. Find the…
At Verilife, there's always a stocked selection of top products & new favorites. Find the…